iRhythm shares plunge 30.7% as Q3 earnings miss estimates
The medical device maker’s stock slid sharply after third-quarter results failed to meet analyst expectations, erasing half its value over the past year.
The medical device maker’s stock slid sharply after third-quarter results failed to meet analyst expectations, erasing half its value over the past year. Published 2026-11-08 by Falling Shares.
| By Falling Shares Intelligence, edited by Wung Thomas, Editor-in-Chief
Written by Falling Shares Intelligence, our automated newsroom, from the public sources listed below and live market data. Every figure is checked against that material before publication, but the story has not been reviewed by a human editor. Check the linked sources before relying on it, and report errors to info@fallingshares.com.
iRhythm Holdings shares fell 30.7% on Friday after the company reported third-quarter earnings that missed estimates, according to Zacks. The drop wiped out more than half the company’s value over the past 12 months, leaving the stock 52.3% below its 52-week high.
Q3 results trigger sell-off
iRhythm Holdings reported third-quarter results that fell short of analyst forecasts, triggering a sharp sell-off in the stock. The company’s share price closed at $90.22, a decline of 30.70% on the day. Trading volume reached 5,667,138 shares, significantly higher than the daily average.
GlobeNewswire reported that iRhythm is scheduled to participate in upcoming investor conferences, though no specific dates or locations were provided in the summary. The company did not issue an immediate statement explaining the severity of the sell-off beyond the earnings data.
Company-specific decline
The 30.7% fall was entirely company-specific, according to Falling Shares’ move attribution. The broader S&P 500 rose 0.3% in the same session, while the US Health Care sector (XLV) dipped 0.1%. This indicates the decline was driven by factors internal to iRhythm rather than market-wide or sector-wide trends.
Falling Shares rates the stock as Unstable, citing an annualised volatility of 84.7% compared to 13.7% for the benchmark index. The stock has recorded 12 sessions with moves of 5% or more in the past six months. Over the last year, the share price has fallen 50.0%, and it is currently 25.6% below its 200-day average.